Skip to content
Open access

Cefepime exposure in prolonged or intermittent infusion in critically ill children.

Sep 2026 · British Journal of Clinical Pharmacology · 1 citation · 20 references
Medicine

Abstract

Aims

Cefepime is commonly used in critically ill children for whom there is a high between-subject variability. To reach the therapeutic pharmacokinetic (PK) target in critically ill patients, prolonged infusion of beta-lactams seems to be the most efficient. The aim of this study was to compare cefepime exposure between prolonged and intermittent infusions in critically ill children.

Methods

This prospective observational study was conducted in two paediatric intensive care units. Children with a cefepime plasma concentration measurement were included. Steady-state free residual and plateau concentrations were estimated using Bayesian forecasting. The PK target was defined as 100% fT≥4xMIC. Exposure was compared using the minimum inhibitory concentrations (MICs) of the pathogens identified in the patients. The probability of target attainment (PTA) was also compared using various MICs.

Results

Seventy-eight antibiotic courses in 75 patients were included, divided into 19 prolonged infusions and 59 intermittent infusions. Prolonged and intermittent infusions were comparable for optimal exposure (n = 10/19, 53% vs. n = 35/59, 59%, p = .79). Overexposure tended to be more frequent with prolonged infusion (n = 8/19, 42% vs. n = 16/59, 27%, p = .26), whereas underexposure tended to be less common with prolonged infusion (n = 1/19, 5% vs. n = 8/59, 14%, p = .44). Considering the wide range of MICs, the PTA was comparable for MIC < 1 mg/L but was significantly higher for prolonged infusion for MIC ≥ 1 mg/L (p < .05).

Conclusion

Prolonged infusion of cefepime provides a higher PTA when MIC is ≥1 mg/L compared with intermittent infusion. This result suggests the superiority of prolonged infusion for high MIC bacteria.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.